Oct 22, 2026 06:00AM
Oct 22, 2026 06:00AM
Oct 15, 2026 07:13AM
Oct 13, 2026 06:02AM
Oct 13, 2026 06:00AM
Oct 5, 2026 06:51AM
Sep 29, 2026 07:30AM Cognition Therapeutics schedules FDA meeting on DLB trial endpoints
Sep 29, 2026 07:30AM
Aug 13, 2026 07:05AM
Aug 6, 2026 04:15PM
Jul 13, 2026 07:30AM
Jul 1, 2026 07:05AM
Jun 24, 2026 07:30AM
Jun 24, 2026 07:30AM Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes
Jun 16, 2026 07:31AM
Jun 16, 2026 07:30AM
Jun 1, 2026 07:30AM
May 21, 2026 07:30AM
May 21, 2026 07:30AM
May 14, 2026 07:31AM
May 14, 2026 07:30AM Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
May 7, 2026 04:15PM
Mar 31, 2026 04:31PM
Mar 31, 2026 04:30PM
Mar 26, 2026 07:31AM
Mar 26, 2026 07:30AM
Mar 17, 2026 07:31AM
Mar 17, 2026 07:30AM Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026
Mar 2, 2026 07:31AM
Mar 2, 2026 07:30AM
Feb 5, 2026 07:31AM
Feb 5, 2026 07:30AM
Jan 27, 2026 07:31AM
Jan 27, 2026 07:30AM
Jan 6, 2026 07:30AM Cognition Therapeutics publishes Phase 2 results for DLB treatment
Jan 6, 2026 07:30AM
Dec 3, 2025 07:30AM
Dec 3, 2025 07:30AM
Dec 1, 2025 07:31AM
Dec 1, 2025 07:30AM
Nov 6, 2025 07:30AM
Aug 12, 2025 04:00PM Cognition Therapeutics aligns with FDA on Phase 3 trial design for alzheimer's drug
Aug 12, 2025 04:00PM
Aug 7, 2025 04:00PM
Jul 29, 2025 07:30AM
Jul 21, 2025 07:31AM
Jul 21, 2025 07:30AM
Jul 16, 2025 07:31AM
Jul 16, 2025 07:30AM Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC
Jul 14, 2025 07:07AM

335,386 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All